Followers | 28 |
Posts | 4379 |
Boards Moderated | 1 |
Alias Born | 09/22/2006 |
![](https://investorshub.advfn.com/uicon/82750.png?cb=1713905033)
Friday, December 17, 2021 12:29:34 PM
SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue another opportunity.
Mr. Snyder brings almost thirty years of legal and business experience to Halozyme. Over his career he has led and played key roles in a broad range of intellectual property, licensing, regulatory, anti-trust and litigation matters. Most recently Mr. Snyder served as senior vice president, deputy general counsel, litigation for Qualcomm Incorporated, a large, public, multinational wireless technology company with more than 40,000 employees. In that role Mr. Snyder led litigation strategy for hundreds of cases worldwide, winning key licensing, antitrust, intellectual property and business-related cases. In addition, Mr. Snyder managed Qualcomm's antitrust, legal operations and intellectual property advocacy teams. Prior to working at Qualcomm, Mr. Snyder served in leadership roles at several companies leading legal teams that included overseeing IP strategy development and prosecution. Mr. Snyder received his J.D. from Boston College Law School and M.B.A from Boston College Carroll School of Management. He also holds a B.S. in chemical engineering from the University of Rochester.
"I am delighted to welcome Mark, an accomplished legal and business leader, to our leadership team," said Dr. Helen Torley, president and chief executive officer. "We look forward to Mark's contributions as we benefit from his deep expertise and insights, as we grow the company with the goal of delivering additional value to shareholders. On behalf of the Board, I want to thank Mas for his contributions to Halozyme and wish him all the best in his future endeavors."
"I am pleased to join the outstanding leadership team at Halozyme at such an exciting time in the growth of the company. I look forward to leading the legal team to support that growth," said Mark Snyder.
The more you know, the less you don't know.
Recent HALO News
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 06/25/2024 05:15:00 AM
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy • PR Newswire (US) • 06/21/2024 09:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:15:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/11/2024 08:40:33 PM
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook • PR Newswire (US) • 06/06/2024 12:30:00 PM
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform • PR Newswire (US) • 06/05/2024 08:05:00 PM
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/04/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:24:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 08:08:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:00:43 PM
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® • PR Newswire (US) • 05/21/2024 11:15:00 AM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/08/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:09:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:05:55 PM
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 05/07/2024 08:01:00 PM
- Mahesh Krishnan Elected to Halozyme's Board of Directors • PR Newswire (US) • 04/25/2024 08:45:00 PM
- Halozyme to Report First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 04/23/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 09:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:01:21 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM